Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
Cancers · 25.06.2024 · 16 (13) · 2320
DOI: 10.3390/cancers16132320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.06.2024. Verfasst von Stacey Stauffer und 21 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, 8560 Progress Drive, Frederick, MD 21701,…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Intramural NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Activating mutations in the RAS/MAPK pathway are observed in relapsed neuroblastoma. Preclinical studies indicate that these tumors have an increased sensitivity to inhibitors of the RAS/MAPK pathway, such as MEK inhibitors. MEK inhibitors do not induce durable responses as single agents, indicating a need to identify synergistic combinations of targeted agents to provide therapeutic benefit. We previously showed preclinical therapeutic synergy between a MEK inhibitor, trametinib, and a monoclonal antibody specific for IGF1R, ganitumab in RAS-mutated rhabdomyosarcoma. Neuroblastoma cells, like rhabdomyosarcoma cells, are sensitive to the inhibition of the RAS/MAPK and IGF1R/AKT/mTOR pathways. We hypothesized that the combination of trametinib and ganitumab would be effective in RAS-mutated neuroblastoma. In this study, trametinib and ganitumab synergistically suppressed neuroblastoma cell proliferation and induced apoptosis in cell culture. We also observed a delay in tumor initiation and prolongation of survival in heterotopic and orthotopic xenograft models treated with trametinib and ganitumab. However, the growth of both primary and metastatic tumors was observed in animals receiving the combination of trametinib and ganitumab. Therefore, more preclinical work is necessary before testing this combination in patients with relapsed or refractory RAS-mutated neuroblastoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, 8560 Progress Drive, Frederick, MD 21701, USA.
- Early Translation Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, 9800 Medical Center Drive, Rockville, MD 20850, USA.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
- Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Services, Bethesda, MD 20814, USA.
- Animal Research Technical Support, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
- Small Animal Imaging Program, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
ORCID-Profile: Jacob S Roth, Edjay R Hernandez, Joshua T Kowalczyk, Katie E Hebron, Lilia Ileva, Robert L Kortum, Joseph D Kalen, Elijah F Edmondson, Matthew D Hall
Förderung
- NCI NIH HHS
- Intramural NIH HHS
- National Cancer Institute, National Institutes of Health
- MEY
Zitieren
APA
Stauffer, S., Roth, J. S., Hernandez, E. R., Kowalczyk, J. T., Sealover, N. E., Hebron, K. E., James, A., Isanogle, K. A., Riffle, L. A., Ileva, L., Luo, X., Chen, J. Q., Kedei, N., Kortum, R. L., Lei, H., Shern, J. F., Kalen, J. D., Edmondson, E. F., Hall, M. D., …, & Yohe, M. E. (2024). Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma. Cancers, 16(13), 2320. https://doi.org/10.3390/cancers16132320
Vancouver
Stauffer S, Roth JS, Hernandez ER, Kowalczyk JT, Sealover NE, Hebron KE, et al. Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma. Cancers. 2024;16(13):2320. doi:10.3390/cancers16132320
BibTeX
@article{Stauffer2024,
author = {Stauffer, Stacey and Roth, Jacob S and Hernandez, Edjay R and Kowalczyk, Joshua T and Sealover, Nancy E and Hebron, Katie E and James, Amy and Isanogle, Kristine A and Riffle, Lisa A and Ileva, Lilia and Luo, Xiaoling and Chen, Jin-Qiu and Kedei, Noemi and Kortum, Robert L and Lei, Haiyan and Shern, Jack F and Kalen, Joseph D and Edmondson, Elijah F and Hall, Matthew D and Difilippantonio, Simone and Thiele, Carol J and Yohe, Marielle E},
title = {Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma},
journal = {Cancers},
year = {2024},
volume = {16},
number = {13},
pages = {2320},
doi = {10.3390/cancers16132320}
}
EUVIMED